NCT05679375

Brief Summary

In the current study, the investigators will compare the effects of low-dose intravenous (i.v.) ketamine versus intrathecal Ketamine added to spinal anesthesia on the time to first request for analgesia and maternal pain scores and overall satisfaction in patients undergoing cesarean section.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Feb 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 12, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 11, 2023

Completed
21 days until next milestone

Study Start

First participant enrolled

February 1, 2023

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2024

Completed
Last Updated

March 6, 2025

Status Verified

March 1, 2025

Enrollment Period

1.7 years

First QC Date

December 12, 2022

Last Update Submit

March 4, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time to the first analgesic request

    First Postoperative day

Secondary Outcomes (1)

  • Postoperative pain scores NRS at rest and on movement; (2, 4, 6, 12, and 24 hours) postoperative

    first postoperative day

Study Arms (2)

Intrathecal Ketamine

ACTIVE COMPARATOR

Patients will receive intrathecal Ketamine 0.1mg/kg added to bupivacaine and morphine.

Drug: Intrathecal ketamine

Intravenous ketamine

ACTIVE COMPARATOR

Patients will receive IV Ketamine 0.25mg/kg after spinal anesthesia with bupivacaine and morphine.

Drug: Intravenous ketamine

Interventions

Patients will receive intrathecal Ketamine 0.1mg/kg added to bupivacaine and morphine

Intrathecal Ketamine

Patients will receive IV Ketamine 0.25mg/kg after spinal

Intravenous ketamine

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Pregnant undergoing elective cesarean section

You may not qualify if:

  • Significant coexisting diseases (pregnancy-induced hypertension or diabetes)
  • body mass index ≥40kg/m2, height \<150cm
  • Current use of pain medication including opioids
  • history of substance abuse or hallucinations, cardiovascular disease, diabetes, multiple gestations
  • chronic pain was excluded.
  • contraindications to spinal anaesthesia,
  • severely compromised fetus requiring general anesthesia and those patients who received labor analgesia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut university

Asyut, Egypt

Location

Related Publications (1)

  • Abd El-Rahman AM, Mohamed AA, Mohamed SA, Mostafa MAM. Effect of Intrathecally Administered Ketamine, Morphine, and Their Combination Added to Bupivacaine in Patients Undergoing Major Abdominal Cancer Surgery a Randomized, Double-Blind Study. Pain Med. 2018 Mar 1;19(3):561-568. doi: 10.1093/pm/pnx105.

    PMID: 28520955BACKGROUND

MeSH Terms

Conditions

Agnosia

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

December 12, 2022

First Posted

January 11, 2023

Study Start

February 1, 2023

Primary Completion

October 31, 2024

Study Completion

October 31, 2024

Last Updated

March 6, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations